Jasper Therapeutics Inc (JSPR)vsEli Lilly and Company (LLY)
JSPR
Jasper Therapeutics Inc
$0.66
-5.77%
HEALTHCARE · Cap: $23.46M
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
JSPR
Avoid19
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Trading at 13.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JSPR
The strongest argument for JSPR centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : JSPR
The primary concerns for JSPR are Price/Book, Revenue Growth, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
JSPR profiles as a value stock while LLY is a growth play — different risk/reward profiles.
JSPR carries more volatility with a beta of 3.03 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 19/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jasper Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for patients suffering from severe conditions such as sickle cell disease and specific hematologic malignancies. Leveraging state-of-the-art technologies, Jasper seeks to minimize transplant-related complications, addressing critical unmet needs in the hematology and oncology fields. Supported by a robust intellectual property portfolio and strategic collaborations, the company is well-positioned to drive innovation and propel its clinical pipeline forward, underscoring its commitment to transformative solutions in regenerative medicine.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?